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Volume 60, Number 2 Abstracts 549measure the sensors. The ability to locate and read the signal from each
injected MOXY was characterized. Oxygen data from the MOXYs were
collected throughout the revascularization procedure. The timing of ther-
apy deployment was recorded during the procedure to assess its relationship
with the oxygen data from the MOXYs. Moreover, oxygen data collection
and clinical evaluation were performed immediately postoperatively as well
as on postoperative days 7, 14, 21, and 28. The study protocol was
approved by the CEATE Research Foundation IRB of Costa Rica; informed
consent was obtained from patients before study procedures.
Results: Ten CLI patients (50% male) were enrolled (30% class 4,
70% class 5), and the mean age was 70.7 years (range, 46-90 years). All pa-
tients were Hispanic of varying origins (European and indigenous origins).
MOXYs were successfully read 209 of 212 times (98.6%) in all patients dur-
ing the course of the study. Sensors were compatible with intraoperative use
in the catheterization laboratory and postoperative use in an ofﬁce setting.
In nine of 10 revascularization procedures, at least one of the three MOXYs
showed immediate change in dynamic relative oxygen indices, correlating to
deployed therapy (Fig). There were no adverse events related to the
microsensor materials.
Conclusions: The study results show that use of MOXYs in CLI
merits further testing to determine its potential effect on clinical decision
making that ultimately can lead to improved healing and limb salvage rates.
Fig. An Example of Dynamic Relative Oxygen Indices (DROIDS) versus
Time during endovascular therapy showing the effect of delivered therapy
on local perfusion on the foot.
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Objective: Covered stents are increasingly used to treat femoropopli-
teal occlusive disease. We aimed to determine which clinical variables and
postprocedural pharmacologic regimen provided optimal long-term graft
patency.
Methods: Clinical and angiographic data for consecutive patients
from 2006 to 2012 undergoing superﬁcial femoral artery (SFA) stenting
with Viabahn covered stent grafts were reviewed. Graft patency was deﬁned
as uninterrupted freedom from restenosis or occlusion and was determined
by Kaplan-Meier analysis. The inﬂuence of relevant clinical variables on
patency was determined via univariate and multivariate analyses.
Results: Viabahn stent grafts were placed in 85 limbs in 65 patients
(65% male; mean age, 70 years). Indication for treatment included claudica-
tion (n ¼ 54) or critical limb ischemia (n ¼ 31), with the majority classiﬁed
as TASC II C (n ¼ 30) or D (n ¼ 30) lesions. Mean follow-up was 34
months (range, 12-80 months). Postprocedural pharmacologic regimens
included acetylsalicylic acid (ASA), clopidogrel, and warfarin (49%), ASA
and permanent clopidogrel (44%), or ASA and temporary clopidogrel
(7%). Primary patency rates at 1, 2, and 3 years were 49%, 25%, and 17%,respectively. Secondary patency rates at 1, 2, and 3 years were 69%, 43%,
and 31%, respectively. Multivariate analysis identiﬁed use of 5-mm stents
(hazard ratio, 1.56) as an independent risk factor for loss of patency.
Kaplan-Meier analysis demonstrated signiﬁcantly shorter mean primary
patency among TASC D lesions (17.9 months vs TASC C, 22.4 months
vs TASC A+B, 35.8 months; P ¼ .02) and those taking ASA + temporary
clopidogrel (6.4 months vs ASA + permanent clopidogrel, 24.9 months vs
ASA + clopidogrel + warfarin, 26.9 months; P ¼ .018; Figs 1 and 2).
Eighty-three percent of patients discontinuing clopidogrel within 3 months
of the procedure exhibited loss of primary patency.
Conclusions: Smaller stent size (<6 mm) independently predicted
loss of primary patency. Improved primary patency rates were noted with
non-TASC D lesions and aggressive antiplatelet/anticoagulation regimens.
Patients undergoing SFA stent grafting for occlusive disease should receive
$6-mm-diameter stents and be maintained on clopidogrel for a minimum
of 6 months postprocedure, and potentially lifelong if tolerated.
Fig 1. Primary patency by TASC II classiﬁcation.
Fig 2. Primary patency by pharmacologic regimen.
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Objective: Registries are proven useful to assess clinical outcomes, but
data entry and personnel expenses are a challenge. We developed a registry
to track patients undergoing endovascular aortic aneurysm repair (EVAR) in
an integrated health care system leveraging an electronic medical record
(EMR) to evaluate clinical practices, device performance, surgical
